«Саратовский научно-медицинский журнал» » Архив номеров » Volume 11, issue 3 » Публикация

Поделиться публикацией:
Опубликовать в блог:
Опубликовано 2015-09-25 Опубликовано на SciPeople2016-03-06 21:00:45 ЖурналSaratov Journal of Medical Scientific Research


The combined application of biological therapy and methotrexate in case of escape phenomenon progressing
Ponich E.S., Kruglova L.S., Babushkin A.M. / Антон Киселев контактное лицо
Ponich E.S., Kruglova L.S., Babushkin A.M. The combined application of biological therapy and methotrexate in case of escape phenomenon progressing // Saratov Journal of Medical Scientific Research, Vol. 11, Issue 3, 2015, pp. 405-409
Аннотация

Aim: the study of the efficacy of methotrexate in patients with the "escape effect" during the ustekinumab therapy. Materials and Methods. The results of methotrexate at a dose of 15-20mg/week in treatment of 4 patients receiving biologic and developed "escape effect". Ustekinumab is used as a hypodermic injection at a dose of 45 mg for a body weight of a patient no more than 100 kg, and 90 mg of body weight over 100 kg, at the zero week, the 4th week and then every 12 weeks. Patients control meets the standard management of patients in biological therapy. Results. The study shows that in the case of the resistance progressing when applying preparations of biological therapy, methotrexate is useful at a dose of 15-20mg/week for up to 6 months. The combined use of biologic therapy and methotrexate in the treatment of patients with psoriasis vulgaris, "escape effect" contributes to the marked regression of clinical symptoms and allows to control the process long enough, which is confirmed by the dynamics of the index PASI, BRS and DLQI. The combined method is highly safe, as evidenced by the lack of inhibition of hematopoiesis, the normal level of hepatic transaminases and serum creatinine, which greatly improves patient compliance in this type of therapy. Conclusion. The article presents the data of the combined application of biological medication therapy (ustekinumab) and methotrexate for the treatment of patients with the common form of psoriasis vulgaris. In the case of the development of resistance of biological therapy recommended the appointment of methotrexate. The combined use of methotrexate and biologic therapy in the treatment of patients with psoriasis vulgaris contributes to marked regression of clinical symptoms and allows to control the process for a long time.

Ключевые слова публикации:
               

Нет комментариев

Вам необходимо зайти или зарегистрироваться для комментирования